Prevalence of high‐risk human papillomavirus infection in women with ovarian endometriosis. Issue 1 (8th December 2016)

• Record Type: Journal Article
• Authors: Heidarpour, Mitra; Derakhshan, Maryam; Derakhshan‐Horeh, Marzieh; Kheirollahi, Majid; Dashti, Sepideh
• Is Part Of: Journal of obstetrics and gynaecology research. Volume 43:Issue 1(2017)
• Page Start: 135
• Page End: 139
• Publication Date: 2016-12-08
• Subjects: endometriosis -- high‐risk -- human papillomavirus; Gynecology -- Periodicals; Obstetrics -- Periodicals; 618.1005
• DOI: 10.1111/jog.13188
• Languages: English
• ISSNs: 1341-8076

Abstract

Abstract: Aim: In this study, we aimed to determine the prevalence of human papillomavirus (HPV) in ovarian endometriosis and ovarian tissue from women without endometriosis. Understanding the pathogenesis of the disease could help us design preventative strategies as well as novel and appropriate treatment approaches in this regard. Methods: In this cross‐sectional study, formalin‐fixed and paraffin‐embedded tissue sections from 50 and 49 ovaries with and without endometriosis, respectively, were evaluated for the presence of high‐risk HPV using the polymerase chain reaction technique. Prevalence of HPV infection and other related characteristics of the studied population were compared. Results: High‐risk HPV infection was detected in 13 (26%) and five (10.2%) of the samples with and without endometriosis, respectively ( P = 0.041, χ 2 = 3.16). Mean age and parity were not significantly different in subjects with and without HPV infection in the two studied groups ( P = 0.7 and P = 0.06 for age in case and control groups, respectively; and P = 0.32 and P = 0.09 for parity in case and control groups, respectively). Conclusion: The results of our study indicated a higher rate of high‐risk HPV infection among patients with endometriosis. The findings could provide us baseline information for future studies regarding the pathogenesis of endometriosis and the role of viral infection and their possible impact on future cancer development in this group of patients.